ThermoGenesis: Gains after FDA allows COVID-19 diagnostic kit distribution
** Shares of ThermoGenesis Holdings Inc THMO.O rise 60.13%
to $7.38
** Cell therapy co says received acknowledgment letter from
U.S. Food and Drug Administration (FDA) allowing distribution of
its COVID-19 diagnostic kit urn:newsml:reuters.com:*:nPn9L2Cn2a
** The IgM/IgG Antibody Fast Detection Kit, which delivers
results in less than 10 minutes, has been validated, and
registrations and listings with FDA completed - co
** THMO up ~55% YTD including session's gains
(Reporting by Vishwadha Chander in Bengaluru)
((vishwadha.chander@thomsonreuters.com))
Recent news on Thermogenesis Holdings
See all newsThermogenesis Holdings Inc expected to post earnings of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc reports results for the quarter ended in December - Earnings Summary
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Brief: Thermogenesis Holdings Says On Jan 8 Co Received Nasdaq Letter Notifying It No Longer Complies With Minimum Bid Price Requirement For Listing On Nasdaq